Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pernix to sell Glaxo’s migraine product Treximet in the US

Executive Summary

Only a few months after raising $60mm in financing to support new product acquisitions, spec pharma Pernix Therapeutics Holdings Inc. followed through and received US rights to GlaxoSmithKline PLC’s Treximet (naproxen/sumatriptan), a marketed NSAID/triptan for acute migraine with or without aura.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies